Esophageal Adenocarcinoma Methods and Protocols

Study

Phase

N

Experimental arm

Control arm OS HR OS Exp OS CON OS ab. diff PFS HR PFS Exp PFS CON PFS ab. diff

Subgroup: Chinese

NR

9.7

7.6

2.1

NR

7.2

4.7

2.5

GOLD (2016) [

35

]

III

525 Olaparib

+^

Paclitaxel

Paclitaxel

0.79

8.8

6.9

1.9

0.84

3.7

3.2

0.5

Subgroup: ATM-ve

0.73

12.0

10.0

2

0.74

5.3

3.7

1.6

REGARD (2014) [

25

]

III

355 Ramucirumab

Placebo

0.78

5.2

3.8

1.4

0.48

2.1

1.3

0.8

GRANITE-1 (2013) [

32

] III

656 Everolimus

Placebo

0.90

5.4

4.3

1.1

0.66

1.7

1.4

0.3

APATINIB (2016) [

27

]

III

267 Apatinib

Placebo

0.71

6.5

4.7

1.8

0.44

2.6

1.8

0.8

ONO4538 (2017) [

53

]

III

493 Nivolumab

Placebo

0.63

5.3

4.1

1.2

0.60

1.6

1.5

0.1

Abbreviations:

N

number of patients,

CON

control,

OS

overall survival (in months),

HR

hazard ratio,

OS (Exp)

overall survival in the experimental arm,

OS (ab. diff.)

absolute differ

• 
  

ence of overall survival in two study arms (experimental

−

control),

PFS

progression-free survival,

PFS (Exp)

progression-free survival (in months) the experimental arm,

PFS (ab. diff.)

absolute difference of progression-free survival in two study arms (experimental

−

control),

PF

cisplatin

+

5FU,

PX

cisplatin

+ capecitabine,

IHC

immunohistochemistry,

FISH

flores-

cence in situ hybridization,

CAPOX

capecitabine

+

oxaliplatin,

EOC

epirubicin

+

oxaliplatin

+^

capecitabine,

ECX

epirubicin

+

cisplatin

+

capecitabine

Table 1(continued)